SSA
ZYNE

Schonfeld Strategic Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,400
Closed -$38K – 1958
2020
Q3 		$38K Buy
+11,400
New +$41.9K ﹤0.01% 1309
2017
Q2 		– Sell
-10,162
Closed -$205K – 815
2017
Q1 		$205K Buy
+10,162
New +$202K 0.02% 545

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Schonfeld Strategic Advisors's ZYNE Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2020, closing a stake of 11,400 shares — an estimated $38K sold.

Schonfeld Strategic Advisors first reported a position in ZYNE in Q1 2017 and held it in 2 quarters. The position peaked at $205K in Q1 2017. 58 funds tracked by Wall St. Rank hold ZYNE as of Q4 2020.

  • Schonfeld Strategic Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,400 Zynerba Pharmaceuticals, Inc shares in Q4 2020, an estimated $38K.
  • Schonfeld Strategic Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Zynerba Pharmaceuticals, Inc position peaked at $205K in Q1 2017.
  • 58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.